Stock Analysis

Private companies own 26% of Lepu Medical Technology (Beijing) Co., Ltd. (SZSE:300003) shares but individual investors control 41% of the company

SZSE:300003
Source: Shutterstock

Key Insights

  • Lepu Medical Technology (Beijing)'s significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public
  • A total of 11 investors have a majority stake in the company with 50% ownership
  • Insiders own 14% of Lepu Medical Technology (Beijing)

If you want to know who really controls Lepu Medical Technology (Beijing) Co., Ltd. (SZSE:300003), then you'll have to look at the makeup of its share registry. We can see that individual investors own the lion's share in the company with 41% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Meanwhile, private companies make up 26% of the company’s shareholders.

In the chart below, we zoom in on the different ownership groups of Lepu Medical Technology (Beijing).

See our latest analysis for Lepu Medical Technology (Beijing)

ownership-breakdown
SZSE:300003 Ownership Breakdown September 25th 2024

What Does The Institutional Ownership Tell Us About Lepu Medical Technology (Beijing)?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Lepu Medical Technology (Beijing). This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Lepu Medical Technology (Beijing)'s historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
SZSE:300003 Earnings and Revenue Growth September 25th 2024

We note that hedge funds don't have a meaningful investment in Lepu Medical Technology (Beijing). Looking at our data, we can see that the largest shareholder is China State Shipbuilding Corporation Limited with 13% of shares outstanding. In comparison, the second and third largest shareholders hold about 12% and 6.7% of the stock. Zhongjie Pu, who is the second-largest shareholder, also happens to hold the title of Chief Technology Officer.

After doing some more digging, we found that the top 11 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Lepu Medical Technology (Beijing)

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

It seems insiders own a significant proportion of Lepu Medical Technology (Beijing) Co., Ltd.. It has a market capitalization of just CN¥18b, and insiders have CN¥2.4b worth of shares in their own names. That's quite significant. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

General Public Ownership

The general public-- including retail investors -- own 41% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Company Ownership

It seems that Private Companies own 26%, of the Lepu Medical Technology (Beijing) stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 1 warning sign for Lepu Medical Technology (Beijing) that you should be aware of before investing here.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.